Brief: Alembic Pharmaceuticals Says Completion Of USFDA Inspection At Co's Oncology Formulation Facility
09/10/2024 04:16
Oct 9 (Reuters) - Alembic Pharmaceuticals Ltd ALEM.NS :
* ALEMBIC PHARMACEUTICALS LTD - COMPLETION OF USFDA
INSPECTION AT
CO'S ONCOLOGY FORMULATION FACILITY
* ALEMBIC PHARMACEUTICALS LTD - USFDA INSPECTION INSPECTION
COMPLETED WITHOUT ANY FORM 483 OBSERVATION
Source text for Eikon: ID:nBSE9J20nV
Further company coverage: ALEM.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alembic Pharmaceuticals
See all newsIndia's Alembic Pharma rises after US FDA approves herpesvirus drug
Brief: Alembic Pharmaceuticals Receives USFDA Final Approval For Valganciclovir Oral Solution 50 Mg/Ml
Brief: Alembic Pharmaceuticals Completes USFDA Bioequivalence Inspection At Vadodara With No Observations
India's Alembic Pharma gains as brokerages optimistic after quarterly profit rise
India's Alembic Pharma posts quarterly profit rise on strong generics demand